Aldeyra Therapeutics, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2015 Annual Meeting of Stockholders held on June 9, 2015. Aldeyra Therapeutics, Inc. is a Delaware corporation focused on developing therapies for respiratory diseases.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes
No material financial changes are reported in this filing. The document details the successful ratification of corporate governance proposals at the annual meeting.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, management commentary on operations, or discussion of risks and contingencies. It strictly documents the voting outcomes for the election of directors and the ratification of the independent auditor.
Key Facts for Investor Verification
- Meeting Attendance: 5,419,743 shares (approximately 78.7% of entitled shares) were represented at the meeting, establishing a quorum.
- Director Election: Ben Bronstein, M.D., and Jesse I. Treu, Ph.D., were elected as Class I directors. Dr. Bronstein received 5,073,346 votes for, while Dr. Treu received 5,031,158 votes for.
- Auditor Ratification: Stockholders ratified the appointment of BDO USA, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2015, with 5,412,645 votes for and zero votes against.
- Broker Non-Votes: There were 344,697 broker non-votes recorded for the director election proposal.